Category: Prescription Drugs
Global Prescription Drugs
-
Anemia Drugs
... CAGR of 4.1% over the analysis period 2024-2030. Iron Deficiency Anemia, one of the segments analyzed in the report, is expected to record a 5.1% CAGR and reach US$7.4 Billion by the end of the ... Read More
-
Acute Coronary Syndrome
... at a CAGR of 10.5% over the analysis period 2024-2030. The U.S. Market is Estimated at US$2.6 Billion While China is Forecast to Grow at 16.2% CAGR The Acute Coronary Syndrome market in the U.S. ... Read More
-
Herpes Simplex Virus Infections
... 2030, growing at a CAGR of 3.9% over the analysis period 2024-2030. The U.S. Market is Estimated at US$1.4 Billion While China is Forecast to Grow at 6.6% CAGR The Herpes Simplex Virus Infections market ... Read More
-
Cancer Supportive Care
... at a CAGR of 2.2% over the analysis period 2024-2030. Opioids, one of the segments analyzed in the report, is expected to record a 2.3% CAGR and reach US$11.1 Billion by the end of the ... Read More
-
Acne Drugs
... CAGR of 6.9% over the analysis period 2024-2030. Inflammatory, one of the segments analyzed in the report, is expected to record a 7.6% CAGR and reach US$9.6 Billion by the end of the analysis period. ... Read More
-
e-Prescription Systems
... CAGR of 16.7% over the analysis period 2024-2030. Solutions, one of the segments analyzed in the report, is expected to record a 16.0% CAGR and reach US$3.2 Billion by the end of the analysis period. ... Read More
-
Antibacterial Drugs
... CAGR of 3.8% over the analysis period 2024-2030. ß-lactams, one of the segments analyzed in the report, is expected to record a 4.1% CAGR and reach US$35.4 Billion by the end of the analysis period. ... Read More
-
Antipsychotic Drugs
... CAGR of 6.8% over the analysis period 2024-2030. Second Generation Drugs, one of the segments analyzed in the report, is expected to record a 7.4% CAGR and reach US$15.7 Billion by the end of the ... Read More
-
Medication Management Systems
... at a CAGR of 9.9% over the analysis period 2024-2030. Inventory Management Solutions, one of the segments analyzed in the report, is expected to record a 8.4% CAGR and reach US$2.2 Billion by the end ... Read More
-
Ophthalmic Pharmaceutical Drugs
... at a CAGR of 3.6% over the analysis period 2024-2030. Anti-VEGF Agents, one of the segments analyzed in the report, is expected to record a 4.4% CAGR and reach US$34.3 Billion by the end of ... Read More
-
Antidepressants
... 2.5% over the analysis period 2024-2030. Major Depressive Disorder, one of the segments analyzed in the report, is expected to record a 2.2% CAGR and reach US$7.0 Billion by the end of the analysis period. ... Read More
-
Cancer Cachexia Global Market Report 2025
... is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond. Reasons to Purchase Gain a truly global perspective with the ... Read More
-
Stroke Management
... CAGR of 5.3% over the analysis period 2024-2030. Diagnostics Type, one of the segments analyzed in the report, is expected to record a 5.0% CAGR and reach US$35.9 Billion by the end of the analysis ... Read More
-
Migraine Drugs
... CAGR of 16.0% over the analysis period 2024-2030. Acute Treatment, one of the segments analyzed in the report, is expected to record a 16.6% CAGR and reach US$7.2 Billion by the end of the analysis ... Read More
-
Oral Solid Dosage Contract Manufacturing Global Market Report 2025
... solid dosage contract manufacturing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond. Reasons to Purchase Gain ... Read More
-
Oral Solid Dosage Pharmaceutical Formulation Global Market Report 2025
... solid dosage pharmaceutical formulation market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond. Reasons to Purchase Gain ... Read More
-
Animal Medication
... CAGR of 4.5% over the analysis period 2024-2030. Companion Animals, one of the segments analyzed in the report, is expected to record a 4.8% CAGR and reach US$20.7 Billion by the end of the analysis ... Read More
-
Potassium Bromide
... CAGR of 4.2% over the analysis period 2024-2030. The U.S. Market is Estimated at US$8.5 Million While China is Forecast to Grow at 7.8% CAGR The Potassium Bromide market in the U.S. is estimated at ... Read More
-
Active Pharmaceutical Ingredients (API)
... 2030, growing at a CAGR of 6.3% over the analysis period 2024-2030. Innovative, one of the segments analyzed in the report, is expected to record a 6.0% CAGR and reach US$240.8 Billion by the end ... Read More
-
Cardiovascular Drugs
... CAGR of 3.4% over the analysis period 2024-2030. Anticoagulants, one of the segments analyzed in the report, is expected to record a 3.9% CAGR and reach US$57.7 Billion by the end of the analysis period. ... Read More
-
Antibiotics
... 3.1% over the analysis period 2024-2030. Penicillin, one of the segments analyzed in the report, is expected to record a 3.3% CAGR and reach US$15.7 Billion by the end of the analysis period. Growth in ... Read More
-
Lung Cancer Therapeutics
... at a CAGR of 10.8% over the analysis period 2024-2030. Non-Small-Cell Lung Cancer (NSCLC), one of the segments analyzed in the report, is expected to record a 11.9% CAGR and reach US$82.3 Billion by the ... Read More
-
Tuberculosis Therapeutics
... CAGR of 2.7% over the analysis period 2024-2030. Active TB, one of the segments analyzed in the report, is expected to record a 2.9% CAGR and reach US$654.3 Million by the end of the analysis ... Read More
-
Anxiety Disorder Treatment
... at a CAGR of 2.4% over the analysis period 2024-2030. Antidepressants, one of the segments analyzed in the report, is expected to record a 2.9% CAGR and reach US$4.9 Billion by the end of the ... Read More
-
Pediatric Drugs and Vaccines
... 2030, growing at a CAGR of 5.9% over the analysis period 2024-2030. Conjugate, one of the segments analyzed in the report, is expected to record a 7.0% CAGR and reach US$52.0 Billion by the end ... Read More
Research Assistance
